Latest & greatest articles for colorectal cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on colorectal cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on colorectal cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for colorectal cancer

1. Strategies for Detecting Colorectal Cancer in Patients with Inflammatory Bowel Disease: A Cochrane Systematic Review and Meta-Analysis

Strategies for Detecting Colorectal Cancer in Patients with Inflammatory Bowel Disease: A Cochrane Systematic Review and Meta-Analysis 30353058 2018 10 24 1572-0241 2018 Oct 23 The American journal of gastroenterology Am. J. Gastroenterol. Strategies for Detecting Colorectal Cancer in Patients with Inflammatory Bowel Disease: A Cochrane Systematic Review and Meta-Analysis. 10.1038/s41395-018-0354-7 Patients with longstanding ulcerative colitis (UC) and colonic Crohn's disease (CD) have (...) an increased risk of colorectal cancer (CRC). We assess the effectiveness of endoscopic surveillance in patients with inflammatory bowel disease (IBD) for diagnosing CRC and reducing CRC-related mortality. MEDLINE, EMBASE, and CENTRAL were searched from inception to 19 September 2016. Randomized controlled trials (RCTs), observational cohorts, or case-control studies assessing any form of endoscopic surveillance for early CRC detection were eligible for inclusion; studies without a comparison non

EvidenceUpdates2018

2. SHTG: Colon capsule endoscopy (CCE-2) for the detection of colorectal polyps and cancer in adults

SHTG: Colon capsule endoscopy (CCE-2) for the detection of colorectal polyps and cancer in adults SHTG Advice Statement | 1 Advice Statement 014-18 November 2018 Advice Statement Colon capsule endoscopy (CCE-2) for the detection of colorectal polyps and cancer in adults with signs or symptoms of colorectal cancer or at increased risk of colorectal cancer Advice for NHSScotland Colon capsule endoscopy (CCE-2) is not recommended for routine use in NHSScotland for the detection of colorectal (...) rolling out this technology. The topic was prioritised for inclusion on the SHTG programme following a referral from the Scaling Digital Innovation Service. Evidence Note 86 was produced by Healthcare Improvement Scotland in response to this request. Background Colorectal cancer is the third most common cancer in Scotland with 3,671 new diagnoses in 2015. Colorectal cancer often begins as a growth on the inner lining of the colon, called a polyp. Early detection and removal of precancerous polyps

SHTG Advice Statements2018

3. Screening for Colorectal Cancer

Screening for Colorectal Cancer CLINICAL PRACTICE GUIDELINE Clinical Practice Guideline on Screening for Colorectal Cancer in Individuals With a Family History of Nonhereditary Colorectal Cancer or Adenoma: The Canadian Association of Gastroenterology Banff Consensus Desmond Leddin, 1,2, * David A. Lieberman, 3, * Frances Tse, 4 Alan N. Barkun, 5 Ahmed M. Abou-Setta, 6 John K. Marshall, 4 N. Jewel Samadder, 7 Harminder Singh, 6,8 Jennifer J. Telford, 9 Jill Tinmouth, 10 Anna N. Wilkinson, 11 (...) Department of Family Medicine, University of Ottawa, Ottawa, Ontario, Canada BACKGROUND & AIMS: A family history (FH) of colorectal cancer (CRC) increases the risk of developing CRC. These consensus recommendations developed by the Canadian As- sociation of Gastroenterology and endorsed by the American Gastroenterological Association, aim to provide guidance on screening these high-risk individuals. METHODS: Multiple parallel systematic review streams, informed by 10 literature searches, assembled

Canadian Association of Gastroenterology2018

4. Interim Guidance: Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer

Interim Guidance: Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer 1 Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer Interim Guidance from the Kaiser Permanente National Integrated Cardiovascular Health (ICVH) Work Group October 5, 2018 Three randomized clinical trials (ARRIVE 1 , ASCEND 2 , and ASPREE 3 ) recently published results on aspirin use in patients without known Atherosclerotic Cardiovascular Disease (ASCVD). The studies looked at benefits

Kaiser Permanente National Guideline Program2018

5. Survival differences with immediate versus delayed chemotherapy for asymptomatic incurable metastatic colorectal cancer.

Survival differences with immediate versus delayed chemotherapy for asymptomatic incurable metastatic colorectal cancer. BACKGROUND: For patients with asymptomatic, incurable, metastatic colorectal cancer, palliative, systemic treatment can be started immediately, or can be delayed until disease-related symptoms occur. How the potential survival benefit of starting palliative, systemic treatment immediately after diagnosis weighs up against the potential side effects is currently under debate (...) , and was investigated in this review. OBJECTIVES: To assess the effects of immediate versus delayed chemotherapy, with or without targeted therapy, on overall survival, toxicity, quality of life, progression-free survival, and compliance with chemotherapy for individuals with asymptomatic, metastatic, incurable colorectal cancer. SEARCH METHODS: We searched CENTRAL; 2018, Issue 8, MEDLINE Ovid, Embase Ovid, PsycINFO, the World Health Organization International Clinical Trials Registry Platform

Cochrane2018

6. Bevacizumab (Mvasi) - Metastatic Colorectal Cancer (mCRC) or Locally Advanced, Metastatic or Recurrent Non-small Cell Lung Cancer (NSCLC)

Bevacizumab (Mvasi) - Metastatic Colorectal Cancer (mCRC) or Locally Advanced, Metastatic or Recurrent Non-small Cell Lung Cancer (NSCLC) Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Summary Basis of Decision (SBD) for Contact: Summary basis of decision (SBD) documents provide information related to the original authorization of a product. The for is located

Health Canada - Drug and Health Product Register2018

7. Dental radiograph as an opportunistic screening tool for a colorectal cancer syndrome (CAT#3342)

Dental radiograph as an opportunistic screening tool for a colorectal cancer syndrome (CAT#3342) UTCAT3342, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Dental radiograph as an opportunistic screening tool for a colorectal cancer syndrome Clinical Question Does dental radiograph serve as an opportunistic screening tool for early detection of extraintestinal manifestations of Familial Adenomatous Polyposis (FAP (...) ) in children and adults? Clinical Bottom Line Incidental findings on dental radiographs could serve as screening tools for systemic diseases and syndromes. The attention should be raised when gene mutation, congenitally diseases or familial colorectal cancer are reported by patients during the medical history questionnaire. For patients with risk of FAP, the Dental panoramic radiographic score (DPRS) is inexpensive, and reinforce the referral for the further clinical investigation, gene mapping

UTHSCSA Dental School CAT Library2018

8. Population health interventions to improve colorectal cancer screening by fecal immunochemical tests: A systematic review

Population health interventions to improve colorectal cancer screening by fecal immunochemical tests: A systematic review 30367972 2018 11 16 1096-0260 118 2018 Oct 24 Preventive medicine Prev Med Population health interventions to improve colorectal cancer screening by fecal immunochemical tests: A systematic review. 113-121 S0091-7435(18)30340-2 10.1016/j.ypmed.2018.10.021 Despite clear evidence that colorectal cancer (CRC) screening reduces mortality, screening, including fecal (...) Colorectal cancer Electronic health records Fecal immunochemical test Interventions Population management Screening Systematic review 2018 06 10 2018 09 07 2018 10 20 2018 10 28 6 0 2018 10 28 6 0 2018 10 28 6 0 aheadofprint 30367972 S0091-7435(18)30340-2 10.1016/j.ypmed.2018.10.021

EvidenceUpdates2018

9. Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The Open-Label, Randomized, Phase III TAILOR Trial

Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The Open-Label, Randomized, Phase III TAILOR Trial 30199311 2018 09 10 1527-7755 2018 Sep 10 Journal of clinical oncology : official journal of the American Society of Clinical Oncology J. Clin. Oncol. Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4 (...) ) Versus FOLFOX-4 in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The Open-Label, Randomized, Phase III TAILOR Trial. JCO2018783183 10.1200/JCO.2018.78.3183 Purpose Cetuximab in combination with chemotherapy is a standard-of-care first-line treatment regimen for patients with RAS wild-type (wt) metastatic colorectal cancer (mCRC); however, the efficacy of cetuximab plus leucovorin, fluorouracil, and oxaliplatin (FOLFOX) has never before been proven in a controlled and randomized phase III

EvidenceUpdates2018

10. Evaluation of Interventions Intended to Increase Colorectal Cancer Screening Rates in the United States: A Systematic Review and Meta-analysis

Evaluation of Interventions Intended to Increase Colorectal Cancer Screening Rates in the United States: A Systematic Review and Meta-analysis 30326005 2018 10 19 2168-6114 2018 Oct 15 JAMA internal medicine JAMA Intern Med Evaluation of Interventions Intended to Increase Colorectal Cancer Screening Rates in the United States: A Systematic Review and Meta-analysis. 10.1001/jamainternmed.2018.4637 Colorectal cancer screening (CRC) is recommended by all major US medical organizations but remains (...) underused. To identify interventions associated with increasing CRC screening rates and their effect sizes. PubMed, Cumulative Index to Nursing and Allied Health Literature, the Cochrane Library, and ClinicalTrials.gov were searched from January 1, 1996, to August 31, 2017. Key search terms included colorectal cancer and screening. Randomized clinical trials of US-based interventions in clinical settings designed to improve CRC screening test completion in average-risk adults. At least 2 investigators

EvidenceUpdates2018

11. Influence of Varying Quantitative Fecal Immunochemical Test Positivity Thresholds on Colorectal Cancer Detection: A Community-Based Cohort Study.

Influence of Varying Quantitative Fecal Immunochemical Test Positivity Thresholds on Colorectal Cancer Detection: A Community-Based Cohort Study. Background: The fecal immunochemical test (FIT) is commonly used for colorectal cancer (CRC) screening. Despite demographic variations in stool hemoglobin concentrations, few data exist regarding optimal positivity thresholds by age and sex. Objective: To identify programmatic (multitest) FIT performance characteristics and optimal FIT quantitative (...) hemoglobin positivity thresholds in a large, population-based, screening program. Design: Retrospective cohort study. Setting: Kaiser Permanente Northern and Southern California. Participants: Adults aged 50 to 75 years who were eligible for screening and had baseline quantitative FIT results (2013 to 2014) and 2 years of follow-up. Nearly two thirds (411 241) had FIT screening in the previous 2 years. Measurements: FIT programmatic sensitivity for CRC and number of positive test results per cancer case

Annals of Internal Medicine2018

12. Recent advances in colorectal cancer screening

Recent advances in colorectal cancer screening 30276360 2018 11 14 2589-0514 4 3 2018 Sep Chronic diseases and translational medicine Chronic Dis Transl Med Recent advances in colorectal cancer screening. 139-147 10.1016/j.cdtm.2018.08.004 Li Dan D Department of Gastroenterology, Kaiser Permanente Medical Center, Santa Clara, CA 95051, USA. Division of Research, Kaiser Permanente Northern California, Oakland, CA 94612, USA. eng Editorial 2018 09 17 China Chronic Dis Transl Med 101679934 2095 (...) -882X Colonoscopy Colorectal cancer Screening 2018 06 26 2018 10 3 6 0 2018 10 3 6 0 2018 10 3 6 1 epublish 30276360 10.1016/j.cdtm.2018.08.004 S2095-882X(18)30060-4 PMC6160607 Lancet. 2013 Apr 6;381(9873):1185-93 23414648 Am J Surg Pathol. 2004 Nov;28(11):1452-9 15489648 Gastroenterology. 2016 Nov;151(5):870-878.e3 27443823 CA Cancer J Clin. 2017 May 6;67(3):177-193 28248415 Gastroenterology. 2015 Sep;149(3):777-82; quiz e16-7 26226577 Am J Gastroenterol. 2012 Sep;107(9):1315-29; quiz 1314, 1330

Chronic diseases and translational medicine2018 Full Text: Link to full Text with Trip Pro

13. Effectiveness of a Mailed Colorectal Cancer Screening Outreach Program in Community Health Clinics: The STOP CRC Cluster Randomized Clinical Trial

Effectiveness of a Mailed Colorectal Cancer Screening Outreach Program in Community Health Clinics: The STOP CRC Cluster Randomized Clinical Trial 30083752 2018 09 05 2168-6114 178 9 2018 Sep 01 JAMA internal medicine JAMA Intern Med Effectiveness of a Mailed Colorectal Cancer Screening Outreach Program in Community Health Clinics: The STOP CRC Cluster Randomized Clinical Trial. 1174-1181 10.1001/jamainternmed.2018.3629 Approximately 24 million US individuals receive care at federally qualified (...) health centers, which historically have low rates of colorectal cancer screening. The US Preventive Services Task Force recommends routine colorectal cancer screening for individuals aged 50 to 75 years. To determine the effectiveness of an electronic health record (EHR)-embedded mailed fecal immunochemical test (FIT) outreach program implemented in health centers as part of standard care. This cluster randomized pragmatic clinical trial was conducted in 26 federally qualified health center clinics

EvidenceUpdates2018

14. Revisiting the prognostic relevance of muscle mass among non-metastatic colorectal cancer

Revisiting the prognostic relevance of muscle mass among non-metastatic colorectal cancer 30225389 2018 11 14 2415-1289 3 2018 Translational gastroenterology and hepatology Transl Gastroenterol Hepatol Revisiting the prognostic relevance of muscle mass among non-metastatic colorectal cancer. 55 10.21037/tgh.2018.07.11 Abdel-Rahman Omar O Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt. Department of Oncology, University of Calgary, Tom Baker Cancer Centre (...) Cancer. 2013 Sep 15;119(18):3377-84 23801109 Clin Transl Oncol. 2018 Jun;20(6):794-800 29086248 Cancer. 2018 Jul 15;124(14):3008-3015 29797673 J Gastrointest Cancer. 2013 Jun;44(2):203-10 23264206 Gastrointest Cancer Res. 2007 Nov;1(6):248-53 19262903 J Cachexia Sarcopenia Muscle. 2018 Aug;9(4):664-672 29766660 Clin Colorectal Cancer. 2016 Mar;15(1):16-23 26281943 Ann Oncol. 2013 Oct;24 Suppl 6:vi64-72 24078664 J Nutr. 1994 Jun;124(6):906-10 7515956 J Cancer Surviv. 2012 Dec;6(4):398-406 23054848 Dig

Translational gastroenterology and hepatology2018 Full Text: Link to full Text with Trip Pro

15. Red and processed meat and risk of colorectal cancer: an update

Red and processed meat and risk of colorectal cancer: an update 30190669 2018 11 14 1611-2156 17 2018 EXCLI journal EXCLI J Red and processed meat and risk of colorectal cancer: an update. 792-797 10.17179/excli2018-1554 Benarba Bachir B Laboratory Research on Biological Systems and Geomatics, Faculty of Nature and Life,University of Mascara, Algeria. eng Journal Article 2018 08 08 Germany EXCLI J 101299402 1611-2156 2018 07 22 2018 08 06 2018 9 8 6 0 2018 9 8 6 0 2018 9 8 6 1 epublish 30190669 (...) 10.17179/excli2018-1554 2018-1554 Doc792 PMC6123610 Nutrition. 2018 May;49:17-23 29571606 Eur J Epidemiol. 2017 May;32(5):409-418 28646407 Eur J Cancer. 2018 Feb;90:73-82 29274927 Cancer Epidemiol. 2018 Aug;55:1-7 29753206 J Clin Med. 2018 Jan 30;7(2):null 29385768 Am J Clin Nutr. 2018 Mar 1;107(3):465-479 29566186 Meat Sci. 2014 Aug;97(4):583-96 24769880 PLoS One. 2015 Aug 25;10(8):e0135959 26305323 Clin Nutr. 2017 Jun;36(3):848-852 27206698 Clin Nutr. 2018 Jun;37(3):1019-1026 28526274 Curr Colorectal

EXCLI journal2018 Full Text: Link to full Text with Trip Pro

16. Macrophage repolarisation therapy in colorectal cancer

Macrophage repolarisation therapy in colorectal cancer 30116595 2018 08 17 2059-7029 3 5 2018 ESMO open ESMO Open Macrophage repolarisation therapy in colorectal cancer. e000426 10.1136/esmoopen-2018-000426 Halama Niels N Department of Medical Oncology and Internal Medicine VI, National Center for Tumor Diseases, UniversitatsKlinikum Heidelberg, Heidelberg, Germany. eng Journal Article 2018 08 03 England ESMO Open 101690685 2059-7029 Podcast Competing interests: None declared. 2018 8 18 6 0

ESMO open2018 Full Text: Link to full Text with Trip Pro

17. Incidence of faecal occult blood test interval cancers in population-based colorectal cancer screening: a systematic review and meta-analysis

Incidence of faecal occult blood test interval cancers in population-based colorectal cancer screening: a systematic review and meta-analysis 29934436 2018 06 23 1468-3288 2018 Jun 22 Gut Gut Incidence of faecal occult blood test interval cancers in population-based colorectal cancer screening: a systematic review and meta-analysis. gutjnl-2017-315340 10.1136/gutjnl-2017-315340 Faecal immunochemical tests (FITs) are replacing guaiac faecal occult blood tests (gFOBTs) for colorectal cancer (CRC (...) ) screening. Incidence of interval colorectal cancer (iCRC) following a negative stool test result is not yet known. We aimed to compare incidence of iCRC following a negative FIT or gFOBT. We searched Ovid Medline, Embase, Cochrane Library, Science Citation Index, PubMed and Google Scholar from inception to 12 December 2017 for citations related to CRC screening based on stool tests. We included studies on FIT or gFOBT iCRC in average-risk screening populations. Main outcome was pooled incidence rate

EvidenceUpdates2018

18. Colorectal cancer

Colorectal cancer Top results for colorectal cancer - Trip Database or use your Google+ account Find evidence fast My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box (...) and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for colorectal cancer The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical

Trip Latest and Greatest2018

19. TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer

TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer 30018814 2018 11 14 2059-7029 3 4 2018 ESMO open ESMO Open TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer. e000403 (...) 10.1136/esmoopen-2018-000403 FOLFOXIRI plus bevacizumab is considered a standard option in the upfront treatment of clinically selected patients with metastatic colorectal cancer irrespective of RAS and BRAF molecular status. The randomised MACBETH and VOLFI studies showed that a modified FOLFOXIRI regimen in combination with cetuximab or panitumumab, respectively, achieved high therapeutic activity in RAS and BRAF wild-type patients with an acceptable toxicity profile. Drawing from

ESMO open2018 Full Text: Link to full Text with Trip Pro

20. Colorectal cancer

Colorectal cancer Autosynthesis - Trip Database or use your Google+ account Find evidence fast My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button

Trip Evidence Maps2018